Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Chemotherapy in HER2+ Breast Cancer Post-Trastuzumab
NCT00479856Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in HER2-positive breast cancer, sponsored by GSK. Primary endpoint: Overall Tumor Response. Started Nov 2007; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00479856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479856.